Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

ASCO 2024: Get a sneak peek of Cutting-edge breakthroughs in hematologic malignancies!

Hematologic Malignancies ASCO 2024 Preview

Hematological malignancies, or blood cancers, rank as the fifth most common cancer group in economically developed regions (US, Europe, Japan, and others). The leading pharmaceutical companies such as Janssen, Novartis, Genmab, Pfizer, Innate Pharma, and Sanofi are preparing to unveil their latest data and final analyses at the upcoming conference. The spotlight will be on key abstracts expected to make a lasting impact, generating significant interest and discussion throughout the event.

Our listing includes coverage of abstracts spanning multiple indications, such as Multiple Myeloma, Myelofibrosis, Follicular Lymphoma, Diffuse large B cell Lymphoma, Mycosis Fungoids, Mantle cell lymphoma and others, presenting data readout for classes including bispecific antibodies, CAR T-cell therapies, monoclonal antibodies, anti-KIR3DL2 humanized cytotoxicity-inducing antibody, HDAC inhibitor along with other small molecules. Over the past decade, the treatment landscape for hematologic malignancies has notably expanded, particularly with the emergence of new CAR T-cell therapies, which have significantly improved patient outcomes. However, clinicians often face challenges in selecting the right patients for these therapies, especially among older adults. With the global population aging, there's an increasing need to enhance clinicians' understanding of how to best personalize therapy for older patients with hematologic conditions. The 2024 ASCO Annual Meeting Education Session, titled “How to Optimize and Tailor Therapy to Improve Outcomes in Older Patients With Hematologic Malignancies,” will address this need. It will feature discussions for hematologists and oncologists on the role of geriatric assessments and other strategies to improve treatment decision-making for this growing patient population. Additionally, several other sessions will unveil new insights into the therapeutic development of blood cancers.

In line with this, Delveinsight has curated a list of top abstracts in hematologic malignancies:

Hematologic Malignancies Key Abstracts

Company

Drug

Trial ID/ Acronym

Phase

Abstract ID

Abstract Title

Teclistamab

NCT05552222/

MajesTEC-7

III

Oral Abstract Session - 7506 

Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)

Pelabresib

NCT04603495/

MANIFEST-2

III

Oral Abstract Session - 6502

Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis

Asciminib

NCT04971226

III

Oral Abstract Session - LBA6500

ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results

Brentuximab vedotin

NCT04404283

III

Oral Abstract Session - LBA7005

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

Isatuximab

NCT03319667

/IMROZ

III

Oral Abstract Session - 7500

Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)

Ibrutinib

NCT03112174/

SYMPATICO

III

Oral Abstract Session - 7007

Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study

Tucidinostat

NCT04231448/

DEB

III

Oral Abstract Session - LBA7003

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

TQ-B3525

NCT04324879

II

Poster Session -

40, Abstract- 7057

A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study

Lacutamab

NCT03902184/

TELLOMAK

II

Poster Session -

65, Abstract- 7082

Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial

Epcoritamab

NCT04663347/

EPCORE NHL-2

Ib/II

Poster Session -

65, Abstract- 7082

Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2

Obecabtagene autoleucel

NCT04404660/

AUTO1

I/II

Oral Abstract Session - 6504

Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study

CN201

NCT06189391

I

Poster Session -

23, Abstract- 7040

Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Tags:

Executive Summary

The leading pharmaceutical companies such as Janssen, Novartis, Genmab, Pfizer, Innate Pharma, and Sanofi are preparing to unveil their latest data and final analyses at the upcoming conference.

Recent Articles